Trial Profile
A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Aflibercept/rinucumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms REGN21763AMD
- 05 Aug 2016 According to a Regeneron Pharmaceuticals media release, the company will report results from this study in 2016.
- 17 Nov 2015 New trial record